Dianthus Therapeutics, Inc. /DE/ Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $396.0K | — | -$36.8M | — | -$40.3M | -$0.97 |
| Q2 FY202510-Q · 2025-06-30 | $0 | — | -$31.6M | — | -$34.9M | -$0.88 |
| Q1 FY202510-Q · 2025-03-31 | $0 | — | -$29.5M | — | -$33.2M | -$0.82 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $577.4M | $31.0M | $56.0M | $546.5M |
| Q2 FY202510-Q | $326.1M | $23.0M | $13.2M | $32.0K |
| Q1 FY202510-Q | $348.6M | $20.0M | $10.1M | $32.0K |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | -$40.3M | -$36.8M | — | 42,854,563 |
| Q2 FY202510-Q | -$34.9M | -$31.6M | — | 32,176,482 |
| Q1 FY202510-Q | -$33.2M | -$29.5M | — | 32,125,933 |
Filings
(4)Methodology
Every figure on this page is pulled directly from Dianthus Therapeutics, Inc. /DE/'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].